Agilent earnings analysis: questions answered and next catalysts

Agilent delivered a FY2026 Q3 double beat: EPS $1.62 vs $1.49 (+8.7%) and revenue $1.88B vs $1.84B (+2.2%). The quarter extends a third straight EPS acceleration and supports a recovery track toward FY2026 full-year run-rate around $6.06 for EPS, but margin compression (gross margin 52.4% vs 54.3% in FY2024) and lower free cash flow ($1.15B vs $1.37B) are key watch items. At $157.57, the stock trades at 30.9x trailing P/E (model fair value $145.64, ~-7.6% overvalued), implying further upside likely depends on margin/profitability re-rating alongside the revenue rebound; next major catalyst is the FY2026 Q4 print on Nov 30.

Analysis

This is a quality-of-earnings rather than a pure top-line story. The market can keep rewarding the name for one or two sessions because the recovery narrative is now credible, but the harder question is whether the company is getting real operating leverage or just cycling easier comps. With gross margin and FCF still slipping, the valuation is already leaning on a margin-repair story that has not yet shown up in the numbers.

Second-order, the signal matters more for the broader lab-tools complex than for one stock: if demand is truly improving, better-capitalized peers with stronger recurring revenue and pricing power should win the next leg of multiple expansion. If not, this becomes a selective-share-gain environment where TMO, DHR, and WAT can still take share while smaller/more cyclical players struggle to convert volume into earnings. The key tell over the next 1-3 months is whether guidance implies margin expansion, not just revenue acceleration.

The contrarian view is that the market is overpaying for visible recovery and underweighting mix risk. At ~31x trailing earnings, A needs a clean FY2027 guide or a noticeable gross-margin inflection to justify upside; absent that, the stock can drift back toward fair value even if the next print is fine. The cleanest falsifier is a guided FY2027 EPS step-up without margin improvement, which would validate the rerating case and force shorts to cover into year-end.

Key Decisions for Investors

• No aggressive long here: treat the print as confirmation, not initiation. If owning A, tighten risk ahead of the November guidance print; downside risk/reward is poor above ~$155 unless gross margin inflects.
• Relative-value trade: short A / long TMO or DHR over the next 1-3 months to express a view that A's recovery is already priced while higher-quality peers deserve the rerating. Use any post-earnings strength as the entry window.
• For tactical upside, consider a small A call spread into the next 2-6 weeks only if the stock holds above the post-print gap and management reiterates FY2027 margin expansion. Falsify if margin commentary stays flat or weaker.
• Watch the November FY2026 Q4 print as the real catalyst; if gross margin does not recover sequentially and FCF remains sub-FY2024 levels, expect multiple compression back toward the mid-20s.
• Do not use NVDA as a read-through. The AI linkage looks superficial here; this is a lab-capex / instrument-cycle trade, not an AI beta trade.